These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37018923)

  • 1. Efficacy of pentasodium diethylenetriamine pentaacetate in ameliorating anosmia post COVID-19.
    Imam MS; Abdelazim MH; Abdelazim AH; Ismaiel WF; Gamal M; Abourehab MAS; Alghamdi S; Alghamdi MA; Ghoneim MM; Elwany S
    Am J Otolaryngol; 2023; 44(4):103871. PubMed ID: 37018923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy of Sodium Phytate as a Natural Chelating Agent in Reducing Elevated Calcium Levels in Nasal Mucus Among Individuals Experiencing Olfactory Dysfunction Following COVID-19: A Prospective Randomized Double-Controlled Clinical Trial.
    Altemani AH; Alanazi MA; Altemani AH; Alharbi A; Alsahali S; Alotaib NM; Abdelazim MH
    Am J Rhinol Allergy; 2024 Mar; 38(2):116-122. PubMed ID: 38105576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Sodium Gluconate on Decreasing Elevated Nasal Calcium and Improving Olfactory Function Post COVID-19 Infection.
    Abdelazim MH; Abdelazim AH
    Am J Rhinol Allergy; 2022 Nov; 36(6):841-848. PubMed ID: 35942688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra Nasal Use of Ethylene Diamine Tetra Acetic Acid for Improving Olfactory Dysfunction Post COVID-19.
    Abdelazim MH; Mandour Z; Abdelazim AH; Ismaiel WF; Gamal M; Abourehab MAS; Alghamdi S; Alghamdi MA; Alrugi RR; Alharthi RR
    Am J Rhinol Allergy; 2023 Nov; 37(6):630-637. PubMed ID: 37786364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intra-nasal nitrilotriacetic acid trisodium salt in lowering elevated calcium cations and improving olfactory dysfunction in COVID-19 patients.
    Abdelazim MH; Abdelazim AH; Ismaiel WF; Alsobky ME; Younes A; Hadeya AM; Ramzy S; Shahin M
    Eur Arch Otorhinolaryngol; 2022 Sep; 279(9):4623-4628. PubMed ID: 35567630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal Corticosteroid Treatment on Recovery of Long-Term Olfactory Dysfunction Due to COVID-19.
    Hosseinpoor M; Kabiri M; Rajati Haghi M; Ghadam Soltani T; Rezaei A; Faghfouri A; Poustchian Gholkhatmi Z; Bakhshaee M
    Laryngoscope; 2022 Nov; 132(11):2209-2216. PubMed ID: 36054369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial.
    Abdelalim AA; Mohamady AA; Elsayed RA; Elawady MA; Ghallab AF
    Am J Otolaryngol; 2021; 42(2):102884. PubMed ID: 33429174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychophysical evaluation of chemosensory functions 5 weeks after olfactory loss due to COVID-19: a prospective cohort study on 72 patients.
    Le Bon SD; Pisarski N; Verbeke J; Prunier L; Cavelier G; Thill MP; Rodriguez A; Dequanter D; Lechien JR; Le Bon O; Hummel T; Horoi M
    Eur Arch Otorhinolaryngol; 2021 Jan; 278(1):101-108. PubMed ID: 32754871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Post-Infectious Anosmia and Hyposmia: A Systematic Review.
    Nag AK; Saltagi AK; Saltagi MZ; Wu AW; Higgins TS; Knisely A; Ting JY; Illing EA
    Ann Otol Rhinol Laryngol; 2023 Jul; 132(7):806-817. PubMed ID: 35959948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olfactory function and viral recovery in COVID-19.
    Mazzoli M; Molinari MA; Tondelli M; Giovannini G; Ricceri R; Ciolli L; Picchetto L; Meletti S
    Brain Behav; 2021 Mar; 11(3):e02006. PubMed ID: 33465295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial.
    Di Stadio A; D'Ascanio L; Vaira LA; Cantone E; De Luca P; Cingolani C; Motta G; De Riu G; Vitelli F; Spriano G; De Vincentiis M; Camaioni A; La Mantia I; Ferreli F; Brenner MJ
    Curr Neuropharmacol; 2022; 20(10):2001-2012. PubMed ID: 35450527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Olfactory Disorders After SARS - CoViD 2 Virus Infection.
    Schmidt F; Azar C; Goektas O
    Ear Nose Throat J; 2024 Jun; 103(1_suppl):48S-53S. PubMed ID: 36976171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics.
    Cantone E; D'Ascanio L; De Luca P; Roccamatisi D; La La Mantia I; Brenner MJ; Di Stadio A
    Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3671-3678. PubMed ID: 38492007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients.
    Singh CV; Jain S; Parveen S
    Am J Otolaryngol; 2021; 42(3):102892. PubMed ID: 33493729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Olfactory Cleft Width and Volumes in Patients with COVID-19 Anosmia and COVID-19 Cases Without Anosmia.
    Tekcan Sanli DE; Altundag A; Yıldırım D; Kandemirli SG; Sanli AN
    ORL J Otorhinolaryngol Relat Spec; 2022; 84(1):1-9. PubMed ID: 34569549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson's disease (PD) do not overlap.
    Morbelli S; Chiola S; Donegani MI; Arnaldi D; Pardini M; Mancini R; Lanfranchi F; D'amico F; Bauckneht M; Miceli A; Biassoni E; Orso B; Barisione E; Benedetti L; Gianmario S; Nobili F
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1939-1950. PubMed ID: 34984501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibody profiles assessment in individuals with persistent olfactory impairment following SARS-CoV-2 infection.
    Fiorelli D; Francavilla B; Velletrani G; Maurantonio S; Passali FM; Bernardini S; Di Girolamo S; Nuccetelli M
    Int Immunopharmacol; 2024 Mar; 129():111599. PubMed ID: 38330796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of intra-nasal tetra sodium pyrophosphate on decreasing elevated nasal calcium and improving olfactory function post COVID-19: a randomized controlled trial.
    Abdelazim MH; Abdelazim AH; Moneir W
    Allergy Asthma Clin Immunol; 2022 Aug; 18(1):67. PubMed ID: 35927706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial.
    Kasiri H; Rouhani N; Salehifar E; Ghazaeian M; Fallah S
    Int Immunopharmacol; 2021 Sep; 98():107871. PubMed ID: 34147912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial.
    Di Stadio A; Gallina S; Cocuzza S; De Luca P; Ingrassia A; Oliva S; Sireci F; Camaioni A; Ferreli F; Mercante G; Gaino F; Pace GM; La Mantia I; Brenner MJ
    Eur Arch Otorhinolaryngol; 2023 Nov; 280(11):4949-4961. PubMed ID: 37380908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.